Study 3 of 3Exenatide literatureLancet (London, England) · Phase 3Top journal2026
Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
Not reported in abstract.
Where it sits
this study against the rest of the exenatide corpus1
Preclinical · this one
1
Observational
0
Open-label
1
Randomised
0
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.00). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
Phase 32026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Exenatide corpus
BAssociation of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study.The lancet. Psychiatry · 2026 · n=167026 · GLP-1 exposure associated with lower rates of alcohol use disorder hospitalizations (RR 0.55, 95% CI 0.43-0.70).HumanAMeal Replacement Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in Adolescents with Severe Obesity.Childhood obesity (Print) · 2023 · n=17 · Mean absolute decrease in BMI of 5.6% [-2.23 kg/m²; 95% CI: -2.45, -2.02; p < 0.001]Human